Fate Therapeutics, Inc. · NASDAQ:FATE
Fate Therapeutics — EULAR European Congress of Rheumatology 2025
13 slides from Fate Therapeutics's conference presentation, Jun 11, 2025
Slide 1: Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
Better Cells For Better Therapies Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy EULAR European Congress of Rheumatology June 11, 2025 Vaneet K Sandhu, MD, MS Fate Therapeutics, Inc. Confidential Information - 1 -
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company’s product candidates, the advancement of and plans and tim
Slide 3: A Unique Platform for the True Delivery of Off-the-Shelf Cellular Therapies
A Unique Platform for the True Delivery of Off-the-Shelf Cellular Therapies Mass Produced, Multiplexed-engineered Cell Products for On-demand Patient Treatment Uniform and Consistent Inventory of Thousands of Platform Advantages Doses Generated per Routine Manufacture ✓ Defined Clonal MCB: Single-ce
Slide 4: FT819: Off-the-Shelf anti-CD19 CAR T-Cell Product Candidate
FT819: Off-the-Shelf anti-CD19 CAR T-Cell Product Candidate Safe and effective targeting of CD19+ B cells with broad patient accessibility in autoimmune True Off-the-Shelf CAR T cell Drug Product Derived from a defined clonal MCB incorporating unique functional elements to balance safety and efficac
Slide 5: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases
FT819-102: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases Uniquely administered with either fludarabine-free conditioning or maintenance therapy in the absence of conditioning NCT06308978 Highly-differentiated therapeutic approach Available on-demand with: • No patient apheresis • L
Slide 6: FT819-102: SLE Disease Characteristics and Patient Characteristics
FT819-102: SLE Disease Characteristics Patient Characteristics Regimen A Regimen B Patient # A1-DL1 A2-DL1 A3-DL1 A1-DL2 B1-DL1 Age, Gender 28 F 22 F 29 F 28 F 23 F BILAG domain for MSK, Renal Renal Renal Cardiorespiratory inclusion Mucocutaneous Disease Duration ~11 years ~4 years ~24 years ~9 year
Slide 7: FT819-102 Preliminary Clinical Safety Data
FT819-102 Preliminary Clinical Safety Data Selected Adverse Events, Highest Grade Reported Regimen A Regimen B Patient A1-DL1 A2-DL1 A3-DL1 A1-DL2 B1-DL1 (conditioning) (Benda) (Cy) (Cy) (Cy) (none) Cytokine Release Syndrome - - - Grade 2 - ICANS - - - - - Graft vs. Host Disease - - - - - Anemia Gra
Slide 8: Patient SLE Case (A1-DL1): 12-month Evaluation
FT819-102 Patient 1 SLE Case (A1-DL1): 12-month Evaluation DORIS remission at 1 year is suggestive of durability of response (Regimen A) ✓ Fludarabine-free lympho-conditioning ✓ On-demand CAR T-cell delivery with no apheresis ✓ No DLT, CRS, GvHD or ICANS ✓ Reduced hospitalization Remission in SLE wi
Slide 9: Patient SLE Case (A1-DL1): 12-month Evaluation, B-cell Immune Reset
FT819-102 Patient 1 SLE Case (A1-DL1): 12-month Evaluation Durability of remission is supported by B-cell immunological reset (Regimen A) Effective B cell depletion and repopulation to normal levels* Reconstituting B cells appear to be predominantly Low pathogenic DN B cell subset in the naïve with
Slide 10: Preliminary Clinical Responses with Fludarabine-free Conditioning
FT819-102 Preliminary Clinical Responses with Fludarabine-free Conditioning Collective reduction in disease burden (Regimen A) ✓ Fludarabine-free lympho-conditioning ✓ On-demand CAR T cell delivery with no apheresis ✓ Reduced hospitalization ✓ Low COGs ($3000/dose) Improved disease activity in all p
Slide 11: Preliminary Observation without the use of Conditioning
FT819-102: Preliminary Observation without the use of Conditioning First patient data suggestive of FT819 treatment response without conditioning chemotherapy (Regimen B) ✓ No lympho-conditioning (Regimen B) ✓ On-demand CAR T cell delivery with no apheresis ✓ No DLT, CRS, GvHD or ICANS ✓ Reduced hos
Slide 12: FT819-102 Summary and Next Steps
FT819-102 Summary and Next Steps • FT819 provides a true off-the-shelf CAR T-cell therapeutic option that overcomes many of the challenges seen in autologous and allogenic cellular therapies • Preliminary clinical data suggests FT819 can support durable clinical activity with less intensive conditio
Slide 13: Acknowledgements
Acknowledgements Patients, Families and The Fantastic People Key Collaborators & Collaboration Sites Treatment Sites of Fate Therapeutics Parastoo Fazeli Jennifer Medlin Debra Zack Rebecca Elstrom Andrew Bitmansour Bertha Villa Lilly Wong John Goulding Nicholas Brookhouser Trever Greene Kyla Omilusi
Fate Therapeutics — EULAR European Congress of Rheumatology 2025 on 6ix